secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001157523-23-000344
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q4 2022 product revenue $262M (+35% YoY); guides 2023 revenue $1.2-1.285B
--------------------------------------------------------------------------------

- Q4 2022 net product revenue $262M; full year $894M (+35% YoY). GAAP net loss $1.13B for 2022 vs $853M in 2021.
- ONPATTRO Q4 rev $122M, AMVUTTRA $69M; total TTR rev $651M for 2022 (+37% YoY).
- sNDA for ONPATTRO in ATTR cardiomyopathy accepted by FDA; PDUFA date Oct 8, 2023; advisory committee planned.
- 2023 guidance: combined net product revenue $1.2B-$1.285B; collaboration and royalty revenue also guided.
- Cash $2.19B at year-end; appointed Carolyn Bertozzi to board; Amy Schulman becomes Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/0001157523-23-000344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000115752323000344/a53337940.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer